Population-based pattern of medication use and prevalence of polypharmacy among patients with cardiovascular diseases: results of the Pars cohort study from Iran

被引:2
作者
Mohsenzadeh, Pooran [1 ]
Ardekani, Ali [2 ]
Poustchi, Hossein [3 ]
Mohammadi, Zahra [3 ]
Abdipour Mehrian, Seyed Reza [1 ,2 ]
Bazrafshan Drissi, Hamed [4 ]
Rahimian, Zahra [5 ]
Taherifard, Erfan [1 ]
Nabavizadeh, Ali [5 ]
Kamalipour, Alireza [6 ]
Mesgarpour, Bita [7 ]
Malekzadeh, Fatemeh [8 ]
Molavi Vardanjani, Hossein [9 ]
机构
[1] Shiraz Univ Med Sci, Sch Med, MPH Dept, Shiraz, Iran
[2] Shiraz Univ Med Sci, Inst Hlth, Hlth Policy Res Ctr, Shiraz, Iran
[3] Univ Tehran Med Sci, Digest Dis Res Inst, Liver & Pancreatobiliary Dis Res Ctr, Tehran, Iran
[4] Shiraz Univ Med Sci, Sch Med, Dept Cardiol, Shiraz, Iran
[5] Shiraz Univ Med Sci, Student Res Comm, Shiraz, Iran
[6] Univ Calif San Diego, Shiley Eye Inst, Hamilton Glaucoma Ctr, Dept Ophthalmol, San Diego, CA 92103 USA
[7] Natl Inst Med Res & Dev NIMAD, Res & Technol, Tehran, Iran
[8] Univ Tehran Med Sci, Shariati Hosp, Digest Dis Res Ctr, Digest Dis Res Inst, Tehran, Iran
[9] Shiraz Univ Med Sci, Res Ctr Tradit Med & Hist Med, Sch Med, MPH Dept, Shiraz, Iran
关键词
Polypharmacy; Medication adherence; Cardiovascular diseases; Prevalence; OLDER-ADULTS;
D O I
10.1186/s12872-022-02872-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Polypharmacy in patients with cardiovascular diseases (CVDs) has been linked to several adverse outcomes. This study aimed to investigate the pattern of medication use and prevalence of polypharmacy among CVDs patients in Iran. Method We used the baseline data of the Pars cohort study (PCS). The participants were asked to bring their medication bags; then, the medications were classified using the Anatomical Therapeutic Chemical classification. Polypharmacy was defined as using five or more medications concurrently. Poisson regression modeling was applied. The adjusted prevalence ratios (PR) and its 95% confidence interval (CI) were estimated. Results Totally, 9262 participants were enrolled in the PCS, of whom 961 had CVDs. The prevalence of polypharmacy in participants with and without CVDs was 38.9% and 7.1%, respectively. The highest prevalence of polypharmacy (51.5%) was among obese patients. Abnormal waist-hip ratio (PR: 2.79; 95% CI 1.57-4.94), high socioeconomic status (PR: 1.65; 95% CI 1.07-2.54), tobacco-smoking (PR: 1.35; 95% CI 1.00-1.81), patients with more than three co-morbidities (PR: 1.41; 95% CI 1.30-1.53), high physical activity (PR: 0.66; 95% CI 0.45-0.95), use of opiate ever (PR: 0.46; 95% CI 0.26-0.82), and healthy overweight subjects (PR: 0.22; 95% CI 0.12-0.39) were associated with polypharmacy. Cardiovascular drugs (76.1%), drugs acting on blood and blood-forming organs (50.4%), and alimentary tract and metabolism drugs (33.9%) were the most frequently used drugs. Agents acting on the renin-angiotensin system were the mostly used cardiovascular system drugs among men and those above 60 years old, while beta-blocking agents were mostly prevalent among cardiovascular system drugs in women with CVDs. Conclusion Given the high prevalence of polypharmacy among CVDs patients, and subsequent complications, programs to educate both physicians and patients to prevent this issue is crucial.
引用
收藏
页数:10
相关论文
共 41 条
  • [1] Abolbashari Mehran, 2017, Cardiovascular & Hematological Agents in Medicinal Chemistry, V15, P31, DOI 10.2174/1871525715666170529093442
  • [2] Determinants of change in polypharmacy status in Switzerland: the population-based CoLaus study
    Abolhassani, Nazanin
    Castioni, Julien
    Marques-Vidal, Pedro
    Vollenweider, Peter
    Waeber, Gerard
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 73 (09) : 1187 - 1194
  • [3] The Profile of Non-Communicable Disease (NCD) research in the Middle East and North Africa (MENA) region: Analyzing the NCD burden, research outputs and international research collaboration
    Aggarwal, Ajay
    Patel, Preeti
    Lewison, Grant
    Ekzayez, Abdulkarim
    Coutts, Adam
    Fouad, Fouad M.
    Shamieh, Omar
    Giacaman, Rita
    Kutluk, Tezer
    Khalek, Rima Abdul
    Lawler, Mark
    Boyle, Peter
    Sarfati, Diana
    Sullivan, Richard
    [J]. PLOS ONE, 2020, 15 (04):
  • [4] Prevalence of polypharmacy and the association with non-communicable diseases in Qatari elderly patients attending primary healthcare centers: A cross-sectional study
    Al-Dahshan, Ayman
    Al-Kubiasi, Noora
    Al-Zaidan, Manal
    Saeed, Wael
    Kehyayan, Vahe
    Bougmiza, Iheb
    [J]. PLOS ONE, 2020, 15 (06):
  • [5] Al-Hashar Amna, 2016, Oman Med J, V31, P421, DOI 10.5001/omj.2016.85
  • [6] Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity
    Alberti, K. G. M. M.
    Eckel, Robert H.
    Grundy, Scott M.
    Zimmet, Paul Z.
    Cleeman, James I.
    Donato, Karen A.
    Fruchart, Jean-Charles
    James, W. Philip T.
    Loria, Catherine M.
    Smith, Sidney C., Jr.
    [J]. CIRCULATION, 2009, 120 (16) : 1640 - 1645
  • [7] Prevalence, Pattern, and Correlates of Polypharmacy among Iranian Type II Diabetic Patients: Results from Pars Cohort Study
    Azadi, Mahbobeh
    Kamalipour, Alireza
    Vardanjani, Hossein Molavi
    Poustchi, Hossein
    Taherifard, Erfan
    Sharifi, Mohammad Hossein
    Salehi, Alireza
    Mohammadi, Zahra
    [J]. ARCHIVES OF IRANIAN MEDICINE, 2021, 24 (09) : 657 - 664
  • [8] Role of the Renin-Angiotensin-Aldosterone System and Its Pharmacological Inhibitors in Cardiovascular Diseases: Complex and Critical Issues
    Borghi C.
    Rossi F.
    Rosei E.A.
    De Luca N.
    Desideri G.B.
    Mancia G.
    Pauletto P.
    Parati G.
    Pontremoli R.
    Schillaci G.
    Stornello M.
    Tocci G.
    Veglio F.
    Virdis A.
    Volpe M.
    Canonico P.L.
    Cirino G.
    Cuzzocrea S.
    Danesi R.
    Di Luca M.
    Forti G.C.
    Genazzani A.
    Leproux G.B.
    Steardo L.
    [J]. High Blood Pressure & Cardiovascular Prevention, 2015, 22 (4) : 429 - 444
  • [9] Prevalence and determinants of polypharmacy in Switzerland: data from the CoLaus study
    Castioni, Julien
    Marques-Vidal, Pedro
    Abolhassani, Nazanin
    Vollenweider, Peter
    Waeber, Gerard
    [J]. BMC HEALTH SERVICES RESEARCH, 2017, 17
  • [10] Medication use and polypharmacy in patients referred to a tertiary gastroenterology practice
    Chris-Olaiya, Abimbola
    Palmer, William
    Stancampiano, Fernando
    Lacy, Brian
    Heckman, Michael
    Chirila, Razvan
    Nikpour, Naveed
    Mcleod, Ethan
    Ryan, Taylor
    Maillis, Alex
    Vargas, Emily
    Bouras, Ernest
    [J]. ROMANIAN JOURNAL OF INTERNAL MEDICINE, 2020, 58 (04) : 228 - 232